Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

globenewswire.com
INDV The article is a press release announcing the date of Indivior's first quarter 2026 financial results report and a webcast. It does not contain any information that suggests a positive or negative outlook on the company's performance or stock.

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Access to the Live Webcast Presentation:

The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.

Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp

Participants may access the presentation telephonically by registering with the following link:

https://register-conf.media-server.com/register/BIea9b995134de41e68f49a057c2a6cb66

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

A replay of the presentation will be available at www.indivior.com.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

For Further Information

Investors:

Jason Thompson

Indivior Pharmaceuticals

Tel: 804-402-7123

E-mail: jason.thompson@indivior.com

Media:

Cassie France-Kelly

Indivior Pharmaceuticals

Tel: 804-594-0836

E-Mail: Indiviormediacontacts@indivior.com